DelveInsight Business Research LLP

DelveInsight has launched a new report on “Myasthenia Gravis (MG) – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Myasthenia Gravis (MG) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Myasthenia Gravis (MG), historical and forecasted epidemiology as well as the  Myasthenia Gravis (MG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

1. DelveInsight estimates suggest that there were ~129,267 prevalent cases of Myasthenia Gravis in 2016 in 7MM. These prevalent cases are further expected to increase and reach up to XXXX cases by 2027

2. United States accounts for the highest prevalent population of Myasthenia Gravis, followed by EU5 and Japan

3. Among the European countries, Spain had the highest prevalent population of Myasthenia Gravis with ~ 15,275 cases, followed by Germany with around 12,400 cases in 2016. France had the lowest prevalent pool of Myasthenia Gravis in 2016.

4.  Japan had the lowest prevalent population of Myasthenia Gravis in 2016 with ~ 14,985 cases      

Key benefits of the report:

1. Myasthenia Gravis (MG) market report covers a descriptive overview and comprehensive insight of the Myasthenia Gravis (MG) epidemiology and Myasthenia Gravis (MG) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Myasthenia Gravis (MG) market report provides insights on the current and emerging therapies.

3. Myasthenia Gravis (MG) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Myasthenia Gravis (MG) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis (MG) market.

Request for sample pages: https://www.delveinsight.com/sample-request/myasthenia-gravis-market

Myasthenia Gravis (MG): Overview

Myasthenia gravis (my-us-THEE-nee-uh GRAY-vis) is characterized by weakness and rapid fatigue of any of the muscles under your voluntary control. It’s caused by a breakdown in the normal communication between nerves and muscles.

There’s no cure for myasthenia gravis, but treatment can help relieve signs and symptoms, such as weakness of arm or leg muscles, double vision, drooping eyelids, and difficulties with speech, chewing, swallowing and breathing.

The key players involved in the Myasthenia Gravis (MG) market:

1. UCB Pharma

2. Novartis

3. Argenx

4. Ra Pharmaceuticals

5. Grifols Therapeutics

6. Catalyst Pharmaceuticals

7. CSL Behring

The launch of the emerging therapies is expected to significantly impact the Myasthenia Gravis (MG) treatment scenario in the upcoming years:-

Drug covered

1. Rozanolixizumab 

2. CFZ533 

3. Efgartigimod 

4. RA101495 

5. IGIV-C 

6. Firdapse

7. Hizentra 

Request a free sample report @https://www.delveinsight.com/sample-request/myasthenia-gravis-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Myasthenia Gravis (MG) Patient Share (%) Overview at a Glance

5. Myasthenia Gravis (MG) Market Overview at a Glance

6. Myasthenia Gravis (MG) Disease Background and Overview

7. Myasthenia Gravis (MG) Epidemiology and Patient Population

8. Country-Specific Patient Population of Myasthenia Gravis (MG)

9. Myasthenia Gravis (MG) Current Treatment and Medical Practices

10. Unmet Needs

11. Myasthenia Gravis (MG) Emerging Therapies

12. Myasthenia Gravis (MG) Market Outlook

13. Country-Wise Myasthenia Gravis (MG) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Myasthenia Gravis (MG) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Myasthenia Gravis (MG) – Pipeline Insights, 2021

“Myasthenia Gravis (MG) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Myasthenia Gravis (MG) market. A detailed picture of the Myasthenia Gravis (MG) pipeline landscape is provided, which includes the disease overview and  Myasthenia Gravis (MG) treatment guidelines.

Myasthenia Gravis (MG) – Epidemiology Forecast to 2030

DelveInsight’s ‘Myasthenia Gravis (MG)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Myasthenia Gravis (MG) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/